<img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=780280282443813&amp;ev=PageView&amp;noscript=1">
search

    Albireo Pharma, Inc.

    verified_userVerify Profile
    Companies » Health Care » Pharmaceuticals & Biotechnology » Pharmaceuticals

    About Albireo Pharma, Inc.

    Albireo is a clinical-stage biopharmaceutical company focused on the development and potential commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and other liver or gastrointestinal diseases and disorders. We have deep expertise in bile acid biology and a pipeline of clinical and nonclinical programs. Our parent company, Albireo Pharma, Inc., is located in Boston, Massachusetts and our key operating subsidiary, Albireo AB, is located in Gothenburg, Sweden. We were spun out from AstraZeneca in 2008. Source

    At A Glance

    • CAPITAL RAISE STATUS
      Not Currently Raising
    • FILING TYPE
      Public
    • PLATFORM TYPE
      NASDAQ
    • RAISED AMOUNT
      $X,XXX,XXX
    • PRE-MONEY EVAULATION
      $X,XXX,XXX
    • SIC CODE
      2834
    • NIN CODE
      ####
    • LEADERSHIP
      Ron Cooper
    • FOUNDED
      2003
    • EMPLOYEES
      20
    • SECTOR
      Pharmaceuticals & Biotechnology
    • SUBSECTOR
      Pharmaceuticals

    Company Tags

    No articles found.

    ESSA Pharma Inc.

    ESSA Pharma Inc.

    With a focus on the development of small molecule drugs for the treatment of cance...

    With a focus on the development of small molecu...

    Filing Type:    PU
    Titan Medical Inc.

    Titan Medical Inc.

    Titan Medical Inc. is a Canadian public company, headquartered in Toronto, Ontario...

    Titan Medical Inc. is a Canadian public company...

    Filing Type:    PU
    Affimed Therapeutics

    Affimed Therapeutics

    At Affimed, we are committed to improving outcomes for patients with cancer. Our s...

    At Affimed, we are committed to improving outco...

    Filing Type:    PU
    Alterity Therapeutics Limited

    Alterity Therapeutics Limited

    We exist to create an alternate future for people living with neurodegenerative di...

    We exist to create an alternate future for peop...

    Filing Type:    PU
    Novus Therapeutics, Inc.

    Novus Therapeutics, Inc.

    Novus Therapeutics, Inc. is a specialty pharmaceutical company focused on developi...

    Novus Therapeutics, Inc. is a specialty pharmac...

    Filing Type:    PU
    Phio Pharmaceuticals Corp.

    Phio Pharmaceuticals Corp.

    Phio Pharmaceuticals is focused on developing the next generation of immuno-oncolo...

    Phio Pharmaceuticals is focused on developing t...

    Filing Type:    PU
    Galectin Therapeutics Inc.

    Galectin Therapeutics Inc.

    Galectin Therapeutics is a biotechnology company focused on discovery and developm...

    Galectin Therapeutics is a biotechnology compan...

    Filing Type:    PU
    Hepion Pharmaceuticals, Inc.

    Hepion Pharmaceuticals, Inc.

    Hepion Pharmaceuticals (Nasdaq: HEPA) is a clinical stage biopharmaceutical compan...

    Hepion Pharmaceuticals (Nasdaq: HEPA) is a clin...

    Filing Type:    PU
    Gemphire Therapeutics Inc.

    Gemphire Therapeutics Inc.

    Gemphire Therapeutics Inc. (NASDAQ:GEMP) is a clinical‑stage biopharmaceutical c...

    Gemphire Therapeutics Inc. (NASDAQ:GEMP) is a c...

    Filing Type:    PU
    Evoke Pharma, Inc.

    Evoke Pharma, Inc.

    Evoke Pharma, Inc. (NASDAQ: EVOK) is a specialty pharmaceutical company focused pr...

    Evoke Pharma, Inc. (NASDAQ: EVOK) is a specialt...

    Filing Type:    PU
    Protagonist Therapeutics, Inc.

    Protagonist Therapeutics, Inc.

    Protagonist Therapeutics is a clinical stage biopharmaceutical company that utiliz...

    Protagonist Therapeutics is a clinical stage bi...

    Filing Type:    PU
    Redhill Biopharma Ltd.

    Redhill Biopharma Ltd.

    RedHill Biopharma Ltd. (NASDAQ: RDHL) (Tel-Aviv Stock Exchange: RDHL) is a special...

    RedHill Biopharma Ltd. (NASDAQ: RDHL) (Tel-Aviv...

    Filing Type:    PU
    ©2026 National Investor Network. All Rights Reserved.